PF | MedChemExpress (MCE) Life Science Reagents

By Targets:	5-HT Receptor (5) Acetyl-CoA Carboxylase (2) Acyltransferase (5) ADC Cytotoxin (2) Adrenergic Receptor (2) Akt (1) AMPK (4) Amyloid-β (1) Anaplastic lymphoma kinase (ALK) (7) Androgen Receptor (3) Antibiotic (6) Antibody-Drug Conjugates (ADCs) (1) Apoptosis (17) Arrestin (1) Aurora Kinase (4) Autophagy (14) Bacterial (8) Bcr-Abl (1) Beta-secretase (1) Biochemical Assay Reagents (1) Btk (2) c-Fms (1) c-Met/HGFR (7) Cannabinoid Receptor (1) Casein Kinase (4) Caspase (1) CCR (6) CDK (4) Checkpoint Kinase (Chk) (1) Cyclic GMP-AMP Synthase (1) Cytochrome P450 (3) Dihydroorotate Dehydrogenase (1) Dipeptidyl Peptidase (1) Dopamine Receptor (7) EGFR (8) Endogenous Metabolite (3) Epigenetic Reader Domain (3) FAAH (4) FAK (9) Fatty Acid Synthase (FASN) (2) FGFR (1) Flavivirus (1) FLT3 (3) Fluorescent Dye (1) Fungal (2) GABA Receptor (2) GCGR (3) GHSR (4) Glucocorticoid Receptor (3) Glucokinase (1) Glutathione Peroxidase (2) GlyT (1) GSK-3 (2) HCV (1) HDAC (1) Histamine Receptor (4) Histone Acetyltransferase (2) Histone Methyltransferase (4) HIV (2) HSP (2) iGluR (2) IKK (3) Indoleamine 2,3-Dioxygenase (IDO) (2) Influenza Virus (2) Interleukin Related (1) IRAK (2) Isotope-Labeled Compounds (4) Itk (1) JAK (10) Kinesin (1) Lipoxygenase (1) LPL Receptor (3) LRRK2 (5) mAChR (2) MAGL (1) MAP3K (1) MAP4K (2) MAPKAPK2 (MK2) (1) Melanocortin Receptor (2) Methionine Adenosyltransferase (MAT) (1) Microtubule/Tubulin (3) Mineralocorticoid Receptor (1) Mitochondrial Metabolism (1) MMP (2) Monoamine Oxidase (1) mTOR (3) nAChR (1) NKCC (3) Opioid Receptor (2) Oxytocin Receptor (5) P2X Receptor (1) p38 MAPK (4) PAK (4) Parasite (18) PARP (7) PD-1/PD-L1 (1) PGE synthase (2) Phosphodiesterase (PDE) (17) Phospholipase (1) PI3K (5) PKA (1) PKC (3) Potassium Channel (2) Progesterone Receptor (2) Prostaglandin Receptor (2) PROTACs (3) Proton Pump (1) Pyk2 (5) Raf (2) RET (1) Ribosomal S6 Kinase (RSK) (1) ROCK (1) ROR (1) ROS Kinase (5) SARS-CoV (4) Ser/Thr Protease (6) SGK (1) SGLT (3) SHP2 (3) Small Interfering RNA (siRNA) (5) Smo (4) Sodium Channel (16) SphK (3) Src (1) TGF-beta/Smad (1) TGF-β Receptor (1) Thyroid Hormone Receptor (1) TNF Receptor (2) Toll-like Receptor (TLR) (3) Topoisomerase (1) Trk Receptor (5) TRP Channel (3) VEGFR (2) Virus Protease (3) γ-secretase (3)
By Research Areas:	Cancer (107) Cardiovascular Disease (24) Endocrinology (20) Infection (36) Inflammation/Immunology (66) Metabolic Disease (49) Neurological Disease (76)
Click Chemistry:	Alkynes (1)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-111371

PF-05180999

PF-999
Phosphodiesterase (PDE) Neurological Disease

PF-05180999 (PF-999) is a phosphodiesterase 2A (PDE2A) inhibitor, with an IC₅₀ of 1.6 nM.
HY-12584

PF-5190457

PF-05190457
GHSR Metabolic Disease Endocrinology

PF-5190457 (PF-05190457) is a potent and selective ghrelin receptor inverse agonist with a pK_i of 8.36 .

PF-05180999 PF-999	Phosphodiesterase (PDE)	Neurological Disease
PF-05180999 (PF-999) is a phosphodiesterase 2A (PDE2A) inhibitor, with an IC₅₀ of 1.6 nM.

PF-5190457 PF-05190457	GHSR	Metabolic Disease Endocrinology
PF-5190457 (PF-05190457) is a potent and selective ghrelin receptor inverse agonist with a pK_i of 8.36 .

HY-14464

PF-00489791 PF-489791	Phosphodiesterase (PDE)	Metabolic Disease
PF-00489791 (PF-489791) is a potent inhibitor of phosphodiesterase 5A with IC₅₀ of 1.5 nM. PF-00489791 can enhance the relaxation of blood vessels within the kidney and so reduce blood pressure, improving renal function .

HY-117623

PF-06685249 PF-249	AMPK	Metabolic Disease
PF-06685249 (PF-249) is a potent and orally active allosteric AMPK activator with an EC₅₀ of 12 nM for recombinant AMPK α1β1γ1. PF-06685249 can be used for diabetic nephropathy research .

HY-11028

PF-02413873 PF-2413873	Progesterone Receptor	Endocrinology
PF-02413873 (PF-2413873) is a potent selective, fully competitive and orally active nonsteroidal progesterone receptor (PR) antagonist, with a K_i of 2.6 nM. PF-02413873 can block progesterone binding and PR nuclear translocation, and inhibit endometrial growth in vivo .

HY-13007

PF-3758309 5+ Cited Publications PF-03758309	PAK Apoptosis	Cancer
PF-3758309 (PF-03758309) is a potent, orally available, and reversible ATP-competitive inhibitor of PAK4 (K_d= 2.7 nM; K_i=18.7 nM). PF-3758309 has the expected cellular functions of a PAK4 inhibitor: inhibition of anchorage-independent growth, induction of apoptosis, cytoskeletal remodeling, and inhibition of proliferation .

HY-13007B

PF-3758309 dihydrochloride PF-03758309 dihydrochloride	PAK Apoptosis	Cancer
PF-3758309 (PF-03758309) dihydrochloride is a potent, orally available, and reversible ATP-competitive inhibitor of PAK4 (K_d= 2.7 nM; K_i=18.7 nM). PF-3758309 dihydrochloride has the expected cellular functions of a PAK4 inhibitor: inhibition of anchorage-independent growth, induction of apoptosis, cytoskeletal remodeling, and inhibition of proliferation .

HY-13007A

PF-3758309 hydrochloride PF-03758309 hydrochloride	PAK Apoptosis	Cancer
PF-3758309 (PF-03758309) hydrochloride is a potent, orally available, and reversible ATP-competitive inhibitor of PAK4 (K_d= 2.7 nM; K_i=18.7 nM). PF-3758309 hydrochloride has the expected cellular functions of a PAK4 inhibitor: inhibition of anchorage-independent growth, induction of apoptosis, cytoskeletal remodeling, and inhibition of proliferation .

HY-120072

PF-3450074 3 Publications Verification PF-74	HIV	Infection
PF-3450074 (PF-74) is a specifical inhibitor of HIV-1 capsid protein (CA) and displays a broad-spectrum inhibition of HIV isolates with submicromolar potency (EC₅₀=8-640 nM). PF-3450074 (PF-74) acts at an early stage of HIV-1 infection, inhibits viral replication by directly competing with the binding of CPSF6 and NUP153, and blocks the uncoating, assembly, and the reverse transcription steps of the viral life cycle . CPSF6: nuclear host factors cleavage and polyadenylation specific factor 6; NUP153: nucleoporin 153.

HY-13810

PF-04880594

Raf Cancer

PF-04880594 is a potent and selective RAF inhibitor. PF-04880594 inhibits both wild-type and mutant BRAF and CRAF. PF-04880594 shows antitumor activity .

PF-04880594	Raf	Cancer
PF-04880594 is a potent and selective RAF inhibitor. PF-04880594 inhibits both wild-type and mutant BRAF and CRAF. PF-04880594 shows antitumor activity .

HY-12883A

PF-05198007	Sodium Channel	Neurological Disease
PF-05198007 is a potent, orally active and selective arylsulfonamide Na_v1.7 inhibitor. PF-05198007 is a compound with a similar pharmacodynamic profile to PF-05089771 .

HY-148531

PF-07054894	CCR	Inflammation/Immunology
PF-07054894 is a potent CCR6 antagonist. PF-07054894 targets G protein-coupled receptor (GPCR). PF-07054894 can be used in research of inflammatory bowel disease .

HY-156193

PF-07208254

Endogenous Metabolite Cardiovascular Disease

PF-07208254 is a potent inhibitor of BDK. PF-07208254 improves cardiometabolic endpoints in mice .

PF-07208254	Endogenous Metabolite	Cardiovascular Disease
PF-07208254 is a potent inhibitor of BDK. PF-07208254 improves cardiometabolic endpoints in mice .

HY-122026

PF-04802367 PF-367	GSK-3	Neurological Disease
PF-04802367 (PF-367) is a highly selective GSK-3 inhibitor with an IC₅₀ of 2.1 nM based on a recombinant human GSK-3β enzyme assay and 1.1 nM based on ADP-Glo assay. PF-04802367 shows desirable central nervous system (CNS) properties and potency. PF-04802367 is equally effective at inhibition of the two known GSK-3 isoforms (GSK-3α and GSK-3β) with IC₅₀ values of 10.0 and 9.0 nM in mobility shift assays, respectively .

HY-19562A

PF-06260933 hydrochloride	MAP4K	Inflammation/Immunology
PF-06260933 hydrochloride is the hydrochloride form of PF-06260933 (HY-19562). PF-06260933 hydrochloride is an orally active and highly selective inhibitor of MAP4K4 with IC₅₀s of 3.7 and 160 nM for kinase and cell, respectively .

HY-10679A

PF-03049423	Phosphodiesterase (PDE)	Neurological Disease
PF-03049423 (Compound PF-5) is a potent and highly selective phosphodiesterase-5A inhibitor with an IC₅₀ of about 0.2 nM for rat and human platelet enzyme. PF-03049423 can be used for the research of acute ischaemic stroke .

HY-103682

PF-06726304 1 Publications Verification	Histone Methyltransferase	Cancer
PF-06726304 is a potent and selective EZH2 inhibitor. PF-06726304 inhibits wild-type and Y641N mutant EZH2 with K_is of 0.7 and 3.0 nM, respectively. PF-06726304 displays robust antitumor growth activity .

HY-103682A

PF-06726304 acetate	Histone Methyltransferase	Cancer
PF-06726304 acetate is a potent and selective EZH2 inhibitor. PF-06726304 acetate inhibits wild-type and Y641N mutant EZH2 with K_is of 0.7 and 3.0 nM, respectively. PF-06726304 acetate displays robust antitumor growth activity .

HY-148353

PF-06455943	LRRK2	Neurological Disease
PF-06455943 is a leucine rich repeat kinase 2 (LRRK2) inhibitor with IC₅₀ value of 3 nM. PF-06455943 also is a PET radioligand. PF-06455943 can be used for the research of ADME/neuro PK characterization and Parkinson disease (PD) .

HY-19985

PF-06459988	EGFR	Cancer
PF-06459988 is an orally activity, irreversible and mutant-selective inhibitor of EGFR mutant forms. PF-06459988 demonstrates high potency and specificity to the T790M-containing double mutant EGFRs. PF-06459988 can be used for the research of cancer .

HY-116625

PF-04628935	GHSR	Neurological Disease
PF-04628935 (compound 10n) is a potent ghrelin receptor inverse agonist, with an IC₅₀ of 4.6 nM. PF-04628935 exhibits oral bioavailability of 43% in rats and shows reasonable penetration into the brain. PF-04628935 can be used for stress and anxiety research .

HY-115506

PF-05105679	TRP Channel	Neurological Disease
PF-05105679 is an orally active and selective TRPM8 antagonist with an IC₅₀ of 103 nM. PF-05105679 has the potential for cold-related pain .

HY-100873

PF-1355 2 Publications Verification PF-06281355	Glutathione Peroxidase	Cardiovascular Disease
PF-1355 is a selective 2-thiouracil mechanism-based MPO inhibitor, used for treatment of vasculitic diseases.

HY-139293

PF-07059013	Others	Cardiovascular Disease
PF-07059013 is an orally active and potent noncovalent modulator of sickled hemoglobin (HbS). PF-07059013 specifically binds to Hb with nanomolar affinity and displays strong partitioning into red blood cells (RBCs). PF-07059013 can be used for sickle cell disease (SCD) research .

HY-148349

PF-07258669	Melanocortin Receptor	Neurological Disease Metabolic Disease
PF-07258669 is a melanocortin-4 receptor (MC4) antagonist. PF-07258669 can be used for the research of cachexia, anorexia, or anorexia nervosa .

HY-18862

PF-03715455
PF-03715455 is a potent inhaled p38 MAPK inhibitor. PF-03715455 shows some selectivity for p38α over p38β with respective IC₅₀ values of 0.88 and 23 nM. PF-03715455 potently inhibits LPS-induced TNFα production in human whole blood (IC₅₀=1.7 nM). PF-03715455 has potential for the treatment of COPD (chronic obstructive pulmonary disease) .

HY-125789

PF-04753299	Bacterial	Infection
PF-04753299 is a potent and selective UDP-3-O-(R-3-hydroxymyristol)-N-acetylglucosamine deacetylase (LpxC) inhibitor. PF-04753299 is bactericidal for the gonococcal isolates. PF-04753299 inhibits E. coli, P. aeruginosa and K. pneumoniae strains with MIC₉₀ values of 2 μg/ml, 4 μg/ml and 16 μg/ml, respectively. PF-04753299 is used for the study of gram-negative bacteria infection .

HY-119103

PF-03246799	5-HT Receptor	Neurological Disease
PF-03246799 (PF-3246799) is a potent and selective 5-HT2C receptor agonist with an EC₅₀ of 190 nM and a K_i of 160 nM. PF-03246799 shows selectivity for 5-HT2C over 5-HT2A and 5-HT2B receptors. PF-03246799 has the potential for stress urinary incontinence (SUI) research .

HY-10032

PF 477736 5 Publications Verification PF 00477736	Checkpoint Kinase (Chk) VEGFR Src c-Fms Aurora Kinase FGFR FLT3 RET CDK	Cancer
PF 477736 (PF 00477736) is a potent, selective and ATP-competitive inhibitor of Chk1, with a K_i of 0.49 nM, it is also a Chk2 inhibitor, with a K_i of 47 nM. PF 477736 shows <100-fold selectivity for Chk1 over VEGFR2, Fms, Yes, Aurora-A, FGFR3, Flt3, and Ret (IC₅₀=8 (K_i), 10, 14, 23, 23, 25, and 39 nM, respectively). PF 477736 can enhance Gemcitabine antitumor activity in vitro and in vivo .

HY-11044

PF-03654746 Tosylate	Histamine Receptor	Neurological Disease Inflammation/Immunology Endocrinology
PF-03654746 Tosylate is a potent and selective histamine H3 receptor antagonist with high brain penetration. PF-03654746 Tosylate reduces allergen-induced nasal symptoms . PF-03654746 Tosylate has potential for treatment of human cognitive disorders, improves cognitive efficacy and disease-modifying effects in Alzheimer's disease (AD) .

HY-14250

PF-998425	Androgen Receptor	Endocrinology
PF-998425 is a potent, selective nonsteroidal androgen receptor (AR) antagonist with an IC₅₀ of 37 nM and 43 nM in AR binding and cellular assays, respectively. PF-998425 has low activity on common receptors and enzymes, such as progesterone receptor. PF-998425 can be used for sebum control and androgenetic alopecia research .

HY-120103

PF-06649298	Sodium Channel	Metabolic Disease
PF-06649298 is a sodium-coupled citrate transporter (NaCT or SLC13A5) inhibitor. PF-06649298 specifically interacts with NaCT with an IC₅₀ value of 16.2 μM to inhibits the transport of citrate in human hepatocytes. PF-06649298 can be used for the research of regulating glucose metabolism and lipid metabolism .

HY-10622

PF-00446687	Melanocortin Receptor	Endocrinology
PF-00446687 is a potent, selective melanocortin-4 receptor (MC4R) agonist with EC50 of 12 ± 1 nM . Pf-446687 is brain penetrant .

HY-12788

PF-04449613	Phosphodiesterase (PDE)	Neurological Disease
PF-04449613 is a selective PDE9A inhibitor with an IC50 of 22 nM[1]. PF-04449613 improved motor learning ability in a mouse model[2].

HY-105507

PF-10040	Others	Inflammation/Immunology
PF-10040 is a quinoline derivative that can inhibit PAF-induced airway hyperresponsiveness. PF-10040 also shows protective effect in experimental NSAID-gastritis .

HY-117048

PF-4191834 PF-04191834	Lipoxygenase	Inflammation/Immunology
PF-4191834 (PF-04191834) is an orally active, noniron chelating, and non-redox inhibitor of the 5-Lipoxygenase (5-LOX) (IC₅₀=229 nM), displays ~300-fold selectivity for 5-LOX over 12-LOX and 15-LOX, shows no activity toward the cyclooxygenase enzymes, and is effective in inflammation and pain .

HY-14380

PF-3845 1 Publications Verification	FAAH Autophagy	Inflammation/Immunology Cancer
PF-3845 is a potent, selective, irreversible and orally active inhibitor of fatty acid amide hydrolase (FAAH), with a K_i of 0.23 µM. PF-3845 is a covalent inhibitor that carbamylates FAAH's serine nucleophile. PF-3845 can reduce pain sensation, inflammation, and anxiety/depression without substantial effects on motility or cognition .

HY-120789

PF-06648671	γ-secretase	Neurological Disease
PF-06648671 is a novel, brain-penetrable, and orally active γ-secretase modulator (GSM). PF-06648671 reduces Aβ42 and Aβ40, with concomitant increases in Aβ37 and Aβ38 in vitro. PF-06648671 is used for the study of Alzheimer’s disease .

HY-11045

PF-03654746	Histamine Receptor	Neurological Disease Inflammation/Immunology Endocrinology
PF-03654746 is a potent and selective histamine H3 receptor antagonist with high brain penetration. PF-03654746 reduces allergen-induced nasal symptoms, might be a novel therapeutic strategy to further explore allergic rhinitis . PF-03654746 improves cognitive efficacy and disease-modifying effects in Alzheimer's disease (AD) .

HY-153963A

PF-06655075 TFA	Oxytocin Receptor	Endocrinology
PF-06655075 (TFA) is the TFA form of PF-06655075 (HY-153963). PF-06655075 is a novel andnon–brain-penetrant oxytocin receptor agonist with increased selectivity for the oxytocin receptor and significantly increased pharmacokinetic stability. PF-06655075 can be used as a tool compound to further explore the role of peripheral oxytocin in behavioral response .

HY-114182

PF-06928215 3 Publications Verification	Cyclic GMP-AMP Synthase	Inflammation/Immunology
PF-06928215 is a cGAS (cyclic GMP-AMP Synthase) inhibitor with an IC₅₀ of 4.9 μΜ. PF-06928215 has a high binding affinity of 0.2 μM (K_d) .

HY-110325

PF-04885614	Sodium Channel	Neurological Disease
PF-04885614 is a potent NaV1.8 inhibitor, extracted from patent US2018328915. PF-04885614 has potential for neurological and neurodevelopmental diseases treatment .

HY-118952

PF-06456384	Sodium Channel	Neurological Disease
PF-06456384 is a highly potent and selective Na_V1.7 inhibitor with an IC₅₀ of 0.01 nM. PF-06456384 has the potential for formalin pain model research .

HY-118952A

PF-06456384 trihydrochloride	Sodium Channel	Neurological Disease
PF-06456384 trihydrochloride is a highly potent and selective Na_V1.7 inhibitor with an IC₅₀ of 0.01 nM. PF-06456384 trihydrochloride has the potential for formalin pain model research .

HY-129787

PF-03550096	Cannabinoid Receptor	Neurological Disease
PF-03550096 is an orally active synthetic cannabinoid (CB) that selectively targets peripheral CB2 receptors with a K_i value of 7.9 nM. PF-03550096 has analgesic activity .

HY-19530

PF-2771	Kinesin	Cancer
PF-2771 is a potent and selective centromere protein E (CENP-E) inhibitor, inhibiting CENP-E motor activity with an IC₅₀ of 16.1 nM; PF-2771 is used as an anticancer agent.

HY-117755

PF-739	AMPK	Metabolic Disease
PF-739 is an orally active and non-selective activator of AMPK. PF-739 activates 12 heterotrimeric AMPK complexes and significantly reduces the level of glucose in plasma complexes .

HY-14296

PF-610355	Adrenergic Receptor	Inflammation/Immunology
PF-610355 is a long-acting inhaled β₂-adrenoreceptor agonist, with an EC₅₀ of 0.26 nM. PF-610355 has the potential for the study of asthma and COPD .

HY-18312

PF-4618433	Pyk2	Metabolic Disease
PF-4618433 is a potent and selective PYK2 inhibitor, with an IC₅₀ of 637 nM. PF-4618433 may be suitable for the research of osteoporosis, craniofacial and appendicular skeletal defects and for targeted bone regeneration .

HY-116524

PF-04781340	5-HT Receptor	Neurological Disease
PF-04781340 is a potent and selective 5-HT2C receptor agonist. PF-04781340 is orally available and have central nervous system penetrant profile .

Cat. No.	Product Name

HY-L125

Anti-Pulmonary Fibrosis Compound Library

1676 compounds

Pulmonary fibrosis (PF), also known as diffuse interstitial pulmonary fibrosis, is a very common end-stage manifestation of several diseases, including idiopathic pulmonary fibrosis (IPF), pulmonary hypertension, and scleroderma, characterised by excessive matrix deposition and destruction of the lung architecture, finally leading to respiratory insufficiency. PF has become a global disease with significantly increased incidence rate, and the most common form of pulmonary fibrosis is idiopathic pulmonary fibrosis (IPF).

Lung fibrosis is a complex disease, a multitude of signal factors and signaling pathways is disrupted in this complex disease, such as TGF-β, Wnt, VEGF and PI3K–Akt. MCE offers a unique collection of 1676 compounds with identified and potential anti-pulmonary fibrosis activity. MCE Anti-Pulmonary Fibrosis Compound Library is a useful tool for anti-pulmonary fibrosis drugs screening and other related research.

Cat. No.	Product Name	Type

HY-W127716

Ru(bpy)2(mcbpy-O-Su-ester)(PF6)2	Fluorescent Dyes/Probes
Ru(bpy)2(mcbpy-O-Su-ester)(PF6)2 is a potent ruthenium-based dye. Ru(bpy)2(mcbpy-O-Su-ester)(PF6)2 can bu used as an effective quencher of quantum dots (QDs) fluorescence and the capture probe of virus antigen EV71. Ru(bpy)2(mcbpy-O-Su-ester)(PF6)2 can be used sensitive electrogenerated chemiluminescence (ECL) labels for detection of matrix metalloproteinases (MMPs) .

Cat. No.	Product Name	Type

HY-W127832

Ru(dpp)3(PF6)2

Biochemical Assay Reagents

Ru(dpp)3(PF6)2 is a biochemical reagent that can be used as a biological material or organic compound for life science related research.

Cat. No.	Product Name	Target	Research Area

HY-P1798

Platelet Factor 4 (58-70), human	Peptides	Cardiovascular Disease
Platelet Factor 4 (58-70), human, a peptide based on the amino acid sequence corresponding to residues 58-70 of platelet factor-4 (PF-4), contains the major heparin-binding domain, which is not sufficient for full antiangiogenic activity .

HY-138687S

Nirmatrelvir-d9

PF-07321332-d9
Isotope-Labeled Compounds Others

Nirmatrelvir-d9 (PF-07321332-d9) is the deuterium labeled Nirmatrelvir (HY-138687) .

HY-P1300

[(pF)Phe4]Nociceptin(1-13)NH2	Opioid Receptor	Neurological Disease
[(pF)Phe4]Nociceptin(1-13)NH2 is a highly potent and selective NOP receptor (OP4) agonist, with a pK_i of 10.68 and a pEC₅₀ of 9.31. [(pF)Phe4]Nociceptin(1-13)NH2 displays high selectivity over δ, κ, and μ opioid receptors (>3000 fold) .

Cat. No.	Product Name	Target	Research Area

HY-P99187

Bococizumab PF-04950615; RN316	Ser/Thr Protease	Cardiovascular Disease Metabolic Disease
Bococizumab (PF-04950615) is an anti-human PCSK9 inhibitory antibody that reduces LDL cholesterol levels. Bococizumab can be used in the research of hypercholesterolemia .

HY-P99828

Cofetuzumab PF-06523435; hu24	Inhibitory Antibodies	Others
Cofetuzumab (PF-06523435) is a humanized IgG1-κ monoclonal antibody targeting PTK7. The expression system of Cofetuzumab is usually CHO (Chinese Hamster Ovary) cells .

HY-P99056

Utomilumab PF 05082566	TNF Receptor	Inflammation/Immunology Cancer
Utomilumab (PF 05082566) is a fully human IgG2 mAb agonist of the T-cell costimulatory receptor 4-1BB/CD137. Utomilumab can be used for the research of relapsed/refractory follicular lymphoma (FL) and other CD20 ⁺ non-Hodgkin lymphomas (NHL) .

HY-P99725

Marstacimab PF-06741086	Inhibitory Antibodies	Metabolic Disease
Marstacimab (PF-06741086) is an anti-tissue factor pathway inhibitor (TFPI) monoclonal antibody. Marstacimab can be used for the research of hemophilia .

HY-P99884

Sasanlimab

PF-06801591
PD-1/PD-L1 Others

Sasanlimab (PF-06801591) is a humanized IgG4-κ antibody targeting PD-1. Mainly expressed by CHO (Chinese Hamster Ovary) cells .

HY-P99216

Ponezumab PF-04360365; RN 1219	EGFR	Neurological Disease
Ponezumab (PF-04360365) is a humanised anti-amyloid IgG2 monoclonal antibody. Ponezumab reduces Aβ levels in the central nervous system and improves performance in mice in various models of learning and memory. Ponezumab can be used in study of Alzheimer's disease .

HY-P99241

Ponsegromab PF 06946860	TGF-beta/Smad	Cancer
Ponsegromab (PF 06946860) is a potent and selective humanized anti-GDF15 antibody inhibitor with anti-cachexia activity. Ponsegromab binds to GDF15 and prevents the binding of GDF15 to GFRAL, thereby blocking GDF15/GFRAL-mediated signaling. Ponsegromab can be used in the research of cancers .

HY-P99353

Ascrinvacumab Anti-ACVRL1 / ALK-1 Reference Antibody (ascrinvacumab); PF-03446962	Anaplastic lymphoma kinase (ALK)	Cancer
Ascrinvacumab (PF-03446962) is a human IgG2 monoclonal antibody targets ALK-1. Ascrinvacumab shows binding efficiency with human ALK1 with a K_d value of 7 nM. Ascrinvacumab can be used for the research of hepatocellular carcinoma (HCC) .

HY-P99829

Cofetuzumab pelidotin PF-06647020; ABBV-647; h6M24-vc0101	Antibody-Drug Conjugates (ADCs) Microtubule/Tubulin	Cancer
Cofetuzumab pelidotin (PF-06647020) is a PTK7-targeting ADC comprising a humanized anti-PTK7 mAb (hu6M024, IgG1) joined to an auristatin microtubule inhibitor payload, auristatin-0101 (Aur0101; HY-12522), by a cleavable valine-citrulline (vc)-based linker. Cofetuzumab pelidotin has a DAR of 4. Cofetuzumab pelidotin binds to cell-surface PTK7 with an EC₅₀ of 1153 pM by flow cytometry. Cofetuzumab pelidotin has the potential for solid tumors research .

HY-P99221

Tanezumab RN-624; PF 4383119	Inhibitory Antibodies	Neurological Disease Inflammation/Immunology
Tanezumab (RN-624) is a humanized anti-NGF mAb with high affinity and specificity. Tanezumab blocks NGF binding to its receptors, p75 and TrkA, in the peripheral nervous system. Tanezumab can be used in studies of acute and chronic pain such as osteoarthritis, knee and neuralgia, as well as post-herpetic neuralgia .

HY-P99527

Vanutide cridificar ACC-001; PF 05236806	Inhibitory Antibodies	Neurological Disease
Vanutide cridificar (ACC-001) is an aminoterminal Aβ1-7 peptide conjugate. Vanutide cridificar can be used for Alzheimer's disease (AD) research .

HY-P99857

Domagrozumab PF-06252616	Inhibitory Antibodies	Metabolic Disease
Domagrozumab is an anti-myostatin humanized monoclonal antibody with a K_D value of 2.6 pM for human myostatin. Domagrozumab induces muscle anabolic activity. Domagrozumab can be used in research of duchenne muscular dystrophy (DMD) .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-156193

PF-07208254	Cardiovascular Disease Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Source classification Endogenous metabolite Disease Research Fields	Endogenous Metabolite
PF-07208254 is a potent inhibitor of BDK. PF-07208254 improves cardiometabolic endpoints in mice .

HY-12361

PF 1022A 1 Publications Verification	Infection Natural Products Microorganisms Classification of Application Fields Source classification Disease Research Fields	Parasite
PF 1022A is a cyclooctadepsipeptide with broadspectrum anthelmintic properties produced by fermentation of the fungus Mycelia sterilia. PF 1022A is a channel-forming ionophore. PF 1022A showes strong anthelmintic activities against *Ascaridia galli* in chickens. PF 1022A also can be used for angiostrongyliasis research .

HY-155156

PF-07238025	Cardiovascular Disease Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Source classification Endogenous metabolite Disease Research Fields	Endogenous Metabolite
PF-07238025 is a BCKDC kinase (BDK) inhibitor (EC₅₀=19 nM). PF-07238025 stabilizes the interaction between BDK and BCKDH core subunit E2 and prevents phosphorylation of E1. While BDK mediates branched-chain ketoacid dehydrogenase (BCKDH) phosphorylation, and inhibition of BCKDH is involved in controlling the rate-limiting step of branched-chain amino acid (BCAA) degradation. Impaired BCAA catabolism has been associated with several diseases, particularly cardiometabolic diseases, including heart failure (HF), type 2 diabetes mellitus (T2DM), non-alcoholic fatty liver disease (NAFLD), and obesity. PF-07238025 improved cardiometabolic endpoints and improves glucose tolerance in mice .

HY-123474

PF-1163B

Structural Classification Microorganisms Ketones, Aldehydes, Acids Source classification

Fungal Antibiotic

PF-1163B is an antifungal antibiotic .

HY-120333

Antibiotic PF 1052	Infection Structural Classification Microorganisms Anti-inflammation/Immunoregulatory Classification of Application Fields Antibiotics Source classification Disease Research Disease Research Fields Other Antibiotics	Antibiotic Fungal Bacterial
Antibiotic PF 1052 is an antibiotic extracted from a natural product library. Antibiotic PF 1052 has an inhibitory effect on murine neutrophil migration .

Species:	Human (8) Virus (1) Mouse (2)
Tag:	His (8) Tag Free (3) Avi (2) Fc (2)
Source:	HEK293 (6) E. coli (7)

Cat. No.	Compare	Product Name	Species	Source

HY-P78289

	PF-4/CXCL4 Protein, Mouse (HEK293, Fc) PF-4; Oncostatin-A; CXCL4; SCYB4; Iroplact; MGC138298	Mouse	HEK293
	PF-4/CXCL4 is a member of the CXC chemokine family that is released from the alpha-granules of activated platelets. PF-4/CXCL4 binds with high affinity to heparin, with antiheparin, antiangiogenic and immunomodulatory activities. PF-4/CXCL4 plays a role in hematopoiesis and immune cell modulation. PF-4/CXCL4 Protein, Mouse (HEK293, Fc) is produced in HEK293 cells with a C-Terminal Fc-tag. It consists of 76 amino acids (V30-S105).

HY-P700981

	PF-4/CXCL4 Protein, Human (Biotinylated, His-Avi) PF-4; Oncostatin-A; CXCL4; SCYB4; Iroplact; MGC138298	Human	E. coli
	Wnt-10b protein is a signaling molecule that plays a key role in embryonic development and tissue homeostasis. It is involved in regulating cell proliferation, differentiation and migration. PF-4/CXCL4 Protein, Human (Biotinylated, His-Avi) is the recombinant human-derived PF-4/CXCL4 protein, expressed by E. coli , with C-Avi, N-His labeled tag. The total length of PF-4/CXCL4 Protein, Human (Biotinylated, His-Avi) is 70 a.a., with molecular weight of 13 kDa.

HY-P70618

	PF-4/CXCL4 Protein, Human (HEK293, His) Platelet Factor 4; PF-4; C-X-C Motif Chemokine 4; Iroplact; Oncostatin-A; PF4; CXCL4; SCYB4	Human	HEK293
	PF-4/CXCL4 is a member of the CXC chemokine family that is released from the alpha-granules of activated platelets. PF-4/CXCL4 binds with high affinity to heparin, with antiheparin, antiangiogenic and immunomodulatory activities. PF-4/CXCL4 plays a role in hematopoiesis and immune cell modulation. PF-4/CXCL4 Protein, Human (HEK293, His) is produced in HEK293 cells with six C-Terminal His-tags. It consists of 70 amino acids (E32-S101).

HY-P76539

	PF4V1 Protein, Human (HEK293, Fc) Platelet factor 4 variant; CXCL4L1; PF4var1; SCYB4V1	Human	HEK293
	PF4V1, also known as CXCL4L1, is a non-allelic variant of CXCL4. PF4V1 is a platelet-associated chemokine, and it binds to heparin is much weaker than in the close homolog PF4/CXCL4. PF4V1 is an inhibitor of angiogenesis and inhibitor of endothelial cell chemotaxis. PF4V1 is involved in inflammation, angiogenesis, and cancer. PF4V1 Protein, Human (HEK293, Fc) is produced in HEK293 cells with a C-Terminal Fc-tag. It consists of 104 amino acids (M1-S104).

HY-P700703

	PF-4/CXCL4 Protein, Human (His-Avi) PF-4; Oncostatin-A; CXCL4; SCYB4; Iroplact; MGC138298	Human	E. coli
	Wnt-10b protein is a signaling molecule that plays a key role in embryonic development and tissue homeostasis. It is involved in regulating cell proliferation, differentiation and migration. PF-4/CXCL4 Protein, Human (His-Avi) is the recombinant human-derived PF-4/CXCL4 protein, expressed by E. coli , with C-Avi, N-His labeled tag. The total length of PF-4/CXCL4 Protein, Human (His-Avi) is 70 a.a., with molecular weight of 10.68 kDa.

HY-P71885

	Platelet factor 4 Protein, Mouse PF4; Cxcl4; Scyb4; Platelet factor 4; PF-4; C-X-C motif chemokine 4	Mouse	E. coli
	Platelet factor 4 (PF4) is released during platelet aggregation and neutralizes the anticoagulant effect of heparin with a higher binding affinity than chondroitin 4-sulfate chains. In addition to its anticoagulant effects, PF4 induces neutrophil and monocyte chemotaxis, thereby promoting immune responses. Platelet factor 4 Protein, Mouse is the recombinant mouse-derived Platelet factor 4 protein, expressed by E. coli , with tag free. The total length of Platelet factor 4 Protein, Mouse is 76 a.a., with molecular weight of ~8.2-12 kDa.

HY-P74637

	pfHPRT Protein, P. falciparum (His) L-lactate dehydrogenase; PF3D7_1324900	Others	E. coli
	pfHPRT Protein, part of the LDH/MDH superfamily, is specified. pfHPRT Protein, P. falciparum (His) is the recombinant pfHPRT protein, expressed by E. coli, with N-His labeled tag. The total length of pfHPRT Protein, P. falciparum (His) is 231 a.a., with molecular weight of ~28.6 kDa.

HY-P77134

	PfLDH Protein, P. falciparum (His) L-lactate dehydrogenase; PF3D7_1324900	Others	E. coli
	pfHPRT Protein, part of the LDH/MDH superfamily, is specified. PfLDH Protein, P. falciparum (His) is the recombinant PfLDH protein, expressed by E. coli, with C-His labeled tag. The total length of PfLDH Protein, P. falciparum (His) is 316 a.a., with molecular weight of ~34.9 KDa.

HY-P76853

	PF-4/CXCL4 Protein, Human C-X-C motif chemokine 4; Oncostatin A; SCYB4	Human	E. coli
	PF-4/CXCL4 is a member of the CXC chemokine family that is released from the alpha-granules of activated platelets. PF-4/CXCL4 binds with high affinity to heparin, with antiheparin, antiangiogenic and immunomodulatory activities. PF-4/CXCL4 plays a role in hematopoiesis and immune cell modulation. PF-4/CXCL4 Protein, Human is produced in E. coli , and consists of 70 amino acids (E32-S101).

HY-P7281

	PF-4/CXCL4 Protein, Human (HEK293) rHuPF-4/CXCL4; C-X-C motif chemokine 4; Oncostatin A; SCYB4	Human	HEK293
	PF-4/CXCL4 is a member of the CXC chemokine family that is released from the alpha-granules of activated platelets. PF-4/CXCL4 binds with high affinity to heparin, with antiheparin, antiangiogenic and immunomodulatory activities. PF-4/CXCL4 plays a role in hematopoiesis and immune cell modulation. PF-4/CXCL4 Protein, Human (HEK293) is produced in HEK293 cells, and consists of 70 amino acids (E32-S101).

HY-P71118

	PFKFB1 Protein, Human (HEK293, His) 6-phosphofructo-2-kinase/fructose-2; 6-bisphosphatase 1; 6PF-2-K/Fru-2; 6-P2ase liver isozyme; Fructose-2; 6-bisphosphatase; PFKFB1; F6PK; PFRX	Human	HEK293
	PFKFB1 protein orchestrates the synthesis and degradation of fructose 2,6-bisphosphate, regulating cellular energy metabolism. Serving as a key enzyme, PFKFB1 modulates fructose 2,6-bisphosphate levels, impacting glycolysis and gluconeogenesis. Its dual role in both synthesis and breakdown is crucial for maintaining cellular energy homeostasis, ensuring adaptability to changing energy demands and environmental conditions. PFKFB1 Protein, Human (HEK293, His) is the recombinant human-derived PFKFB1 protein, expressed by HEK293 , with C-6*His labeled tag. The total length of PFKFB1 Protein, Human (HEK293, His) is 470 a.a., with molecular weight of ~60.0 kDa.

HY-P700046AF

	Animal-Free PF-4/CXCL4 Protein, Human (His) C-X-C motif chemokine 4; Oncostatin A; SCYB4	Human	E. coli
	The PF-4/CXCL4 protein released during platelet aggregation has a crucial impact on physiological processes. It neutralizes the anticoagulant effect of heparin with higher affinity than chondroitin 4-sulfate chains. Animal-Free PF-4/CXCL4 Protein, Human (His) is the recombinant human-derived animal-FreePF-4/CXCL4 protein, expressed by E. coli , with N-His labeled tag. The total length of Animal-Free PF-4/CXCL4 Protein, Human (His) is 70 a.a., with molecular weight of ~8.58 kDa.

HY-P73980

	HA/Hemagglutinin Protein, H5N1 (H8PF45, HA1, HEK293, His) HA; Hemagglutinin; HA/Hemagglutinin Protein, H5N1 (A/Thailand/1(KAN-1)/2004, HA1, HEK293, His)	Virus	HEK293
	HA/Hemagglutinin Protein is pivotal in the viral life cycle, binding to sialic acid receptors and facilitating virus attachment to host cells. This interaction prompts virion internalization through clathrin-dependent or -independent pathways. As a Class I viral fusion protein, it mediates fusion between the virus particle and endosomal membrane, allowing cytoplasmic entry. In endosomes, the low pH induces an irreversible conformational change in HA2, releasing a fusion hydrophobic peptide. Multiple HA protein trimers are essential for forming a competent fusion pore. Its roles in receptor binding, viral internalization, fusion, and membrane penetration are crucial in determining host range restriction and virulence. HA/Hemagglutinin Protein, H5N1 (H8PF45, HA1, HEK293, His) is the recombinant Virus-derived HA/Hemagglutinin protein, expressed by HEK293, with C-His labeled tag. The total length of HA/Hemagglutinin Protein, H5N1 (H8PF45, HA1, HEK293, His) is 340 a.a., with molecular weight of ~38.1 kDa.

Cat. No.	Product Name	Chemical Structure

HY-12522S

PF-06380101-d8 2 Publications Verification
PF-06380101-d₈ is a deuterium labeled PF-06380101. PF-06380101, an Auristatin microtubule inhibitor, is a cytotoxic Dolastatin 10 analogue[1].

HY-50878S

Crizotinib-d5

Crizotinib-d₅ is the deuterium labeled Crizotinib. Crizotinib (PF-02341066) is an orally bioavailable, ATP-competitive ALK and c-Met inhibitor with IC₅₀s of 20 and 8 nM, respectively. Crizotinib inhibits tyrosine phosphorylation of NPM-ALK and tyrosine phosphorylation of c-Met with IC₅₀s of 24 and 11 nM in cell-based assays, respectively. Crizotinib is also a ROS1 inhibitor. Crizotinib has effective tumor growth inhibition .

HY-13272S2

Dacomitinib-d10 dihydrochloride
Dacomitinib-d₁₀ (dihydrochloride) is the deuterium labeled Dacomitinib dihydrochloride. Dacomitinib (PF-00299804) dihydrochloride is a specific and irreversible inhibitor of the ERBB family of kinases with IC50s of 6 nM, 45.7 nM and 73.7 nM for EGFR, ERBB2, and ERBB4, respectively[1].

HY-13272S3

Dacomitinib-d10
Dacomitinib-d₁₀ is deuterium labeled Dacomitinib. Dacomitinib (PF-00299804) is a specific and irreversible inhibitor of the ERBB family of kinases with IC50s of 6 nM, 45.7 nM and 73.7 nM for EGFR, ERBB2, and ERBB4, respectively[1].

HY-15461S

Ertugliflozin-d5
Ertugliflozin-d₅ is the deuterium labeled Ertugliflozin[1]. Ertugliflozin (PF-04971729) is a potent, selective and orally active inhibitor of the sodium-dependent glucose cotransporter 2 (SGLT2), with an IC50 of 0.877 nM for h-SGLT2[2]. Has the potential for the treatment of type 2 diabetes mellitus[3].

HY-10978S

Crisaborole-d4

Crisaborole-d₄ is deuterium labeled Crisaborole. Crisaborole (AN-2728) is a potent inhibitor of PDE4 and cytokine release; inhibit PDE4 with an IC50 of 0.49 μM.
HY-12289S

Defactinib-d6

Defactinib-d6 is a deuterium labeled Defactinib (HY-12289). Defactinib is a novel FAK inhibitor with potential antiangiogenic and antineoplastic activities .

Cat. No.	Product Name	Application	Reactivity

HY-P83411

PF4 Antibody (YA3156)

C-X-C motif chemokine 4; CXCL4; Iroplact; OncostatinA; PF4; Platelet factor 4; SCYB4; short form; Small inducible cytokine subfamily member 4
WB, IHC-P, IP Human, Rat

Cat. No.	Product Name		Classification

HY-120419

PF9601N		Alkynes
PF9601N, an monoamine oxidase B (MAO-B) inhibitor, possesses neuroprotective properties in several in vitro and in vivo models of Parkinson's disease (PD). PF9601N can be used for the research of neurodegenerative diseases mediated by excitotoxicity . PF9601N is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

PF

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Click Chemistry